BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bernstein DI, Pullum DA, Cardin RD, Bravo FJ, Dixon DA, Kousoulas KG. The HSV-1 live attenuated VC2 vaccine provides protection against HSV-2 genital infection in the guinea pig model of genital herpes. Vaccine 2019;37:61-8. [DOI: 10.1016/j.vaccine.2018.11.042] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 Wan M, Yang X, Sun J, Ding X, Chen Z, Su W, Cai L, Hou A, Sun B, Gao F, Jiang C, Zhou Y. An Adenovirus-Based Recombinant Herpes Simplex Virus 2 (HSV-2) Therapeutic Vaccine Is Highly Protective against Acute and Recurrent HSV-2 Disease in a Guinea Pig Model. Viruses 2023;15. [PMID: 36680259 DOI: 10.3390/v15010219] [Reference Citation Analysis]
2 Abeywickrema M, Kelly D, Kadambari S. Management of neonatal central nervous system viral infections: Knowledge gaps and research priorities. Rev Med Virol 2023;:e2421. [PMID: 36639694 DOI: 10.1002/rmv.2421] [Reference Citation Analysis]
3 Stanfield BA, Bravo FJ, Dixon DA, Chouljenko VN, Kousoulas KG, Bernstein DI. Cross protective efficacy of the Non-Neurotropic live attenuated herpes simplex virus type 1 vaccine VC-2 is enhanced by intradermal vaccination and deletion of glycoprotein G. Vaccine 2022;40:6093-9. [PMID: 36114130 DOI: 10.1016/j.vaccine.2022.09.015] [Reference Citation Analysis]
4 Pataki Z, Rebolledo Viveros A, Heldwein EE. Herpes Simplex Virus 1 Entry Glycoproteins Form Complexes before and during Membrane Fusion. mBio 2022;:e0203922. [PMID: 35972147 DOI: 10.1128/mbio.02039-22] [Reference Citation Analysis]
5 Dhanushkodi N, Prakash S, Srivastava R, Coulon PA, Vahed H, Zayou L, Quadiri A, Schaefer H, Benmohamed L. A Prime/Pull RR2/CXCL11 Therapeutic Vaccine that Bolsters the Number and Function of Dorsal Root Ganglia Tissue-Resident HSV-Specific CD8+ TRM Cells Protects Latently Infected Guinea Pigs from Recurrent Genital Herpes.. [DOI: 10.1101/2022.07.22.501208] [Reference Citation Analysis]
6 Pataki Z, Viveros AR, Heldwein EE. Herpes simplex virus 1 entry glycoproteins form stable complexes prior to and during membrane fusion.. [DOI: 10.1101/2022.05.07.491029] [Reference Citation Analysis]
7 Uche IK, Stanfield BA, Rudd JS, Kousoulas KG, Rider PJF. Utility of a Recombinant HSV-1 Vaccine Vector for Personalized Cancer Vaccines. Front Mol Biosci 2022;9:832393. [DOI: 10.3389/fmolb.2022.832393] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Traidl S, Roesner L, Zeitvogel J, Werfel T. Eczema herpeticum in atopic dermatitis. Allergy 2021;76:3017-27. [PMID: 33844308 DOI: 10.1111/all.14853] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
9 Jambunathan N, Clark CM, Musarrat F, Chouljenko VN, Rudd J, Kousoulas KG. Two Sides to Every Story: Herpes Simplex Type-1 Viral Glycoproteins gB, gD, gH/gL, gK, and Cellular Receptors Function as Key Players in Membrane Fusion. Viruses 2021;13:1849. [PMID: 34578430 DOI: 10.3390/v13091849] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Stanfield BA, Kousoulas KG, Fernandez A, Gershburg E. Rational Design of Live-Attenuated Vaccines against Herpes Simplex Viruses. Viruses 2021;13:1637. [PMID: 34452501 DOI: 10.3390/v13081637] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
11 Wijesinghe VN, Farouk IA, Zabidi NZ, Puniyamurti A, Choo WS, Lal SK. Current vaccine approaches and emerging strategies against herpes simplex virus (HSV). Expert Rev Vaccines 2021;:1-20. [PMID: 34296960 DOI: 10.1080/14760584.2021.1960162] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Rider PJ, Dulin H, Uche IK, Mcgee MC, Breitenstein B, Tan GS, Huang W, Kousoulas KG, Hai R. A Herpes Simplex Virus Type-1-derived influenza vaccine induces balanced adaptive immune responses and protects mice from lethal influenza virus challenge.. [DOI: 10.1101/2021.08.05.455241] [Reference Citation Analysis]
13 Uche IK, Fowlkes N, Vu L, Watanabe T, Carossino M, Nabi R, Del Piero F, Rudd JS, Kousoulas KG, Rider PJF. Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model. J Virol 2021;95:e01359-20. [PMID: 33177208 DOI: 10.1128/JVI.01359-20] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
14 Bernstein DI, Cardin RD, Smith GA, Pickard GE, Sollars PJ, Dixon DA, Pasula R, Bravo FJ. The R2 non-neuroinvasive HSV-1 vaccine affords protection from genital HSV-2 infections in a guinea pig model. NPJ Vaccines 2020;5:104. [PMID: 33298966 DOI: 10.1038/s41541-020-00254-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
15 Xu X, Feng X, Wang L, Yi T, Zheng L, Jiang G, Fan S, Liao Y, Feng M, Zhang Y, Li D, Li Q. A HSV1 mutant leads to an attenuated phenotype and induces immunity with a protective effect. PLoS Pathog 2020;16:e1008703. [PMID: 32776994 DOI: 10.1371/journal.ppat.1008703] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 Kim HC, Lee HK. Vaccines against Genital Herpes: Where Are We? Vaccines (Basel) 2020;8:E420. [PMID: 32727077 DOI: 10.3390/vaccines8030420] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
17 Ayoub HH, Chemaitelly H, Abu-Raddad LJ. Epidemiological Impact of Novel Preventive and Therapeutic HSV-2 Vaccination in the United States: Mathematical Modeling Analyses. Vaccines (Basel) 2020;8:E366. [PMID: 32650385 DOI: 10.3390/vaccines8030366] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
18 Bernstein DI. Use of the Guinea pig model of genital herpes to evaluate vaccines and antivirals: Review. Antiviral Res 2020;180:104821. [PMID: 32544409 DOI: 10.1016/j.antiviral.2020.104821] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
19 Ike AC, Onu CJ, Ononugbo CM, Reward EE, Muo SO. Immune Response to Herpes Simplex Virus Infection and Vaccine Development. Vaccines (Basel) 2020;8:E302. [PMID: 32545507 DOI: 10.3390/vaccines8020302] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
20 Awasthi S, Hook LM, Pardi N, Wang F, Myles A, Cancro MP, Cohen GH, Weissman D, Friedman HM. Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes. Sci Immunol 2019;4:eaaw7083. [PMID: 31541030 DOI: 10.1126/sciimmunol.aaw7083] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 16.7] [Reference Citation Analysis]
21 Srivastava R, Coulon PA, Prakash S, Dhanushkodi NR, Roy S, Nguyen AM, Alomari NI, Mai UT, Amezquita C, Ye C, Maillère B, BenMohamed L. Human Epitopes Identified from Herpes Simplex Virus Tegument Protein VP11/12 (UL46) Recall Multifunctional Effector Memory CD4+ TEM Cells in Asymptomatic Individuals and Protect from Ocular Herpes Infection and Disease in "Humanized" HLA-DR Transgenic Mice. J Virol 2020;94:e01991-19. [PMID: 31915285 DOI: 10.1128/JVI.01991-19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
22 Egan K, Hook LM, LaTourette P, Desmond A, Awasthi S, Friedman HM. Vaccines to prevent genital herpes. Transl Res 2020;220:138-52. [PMID: 32272093 DOI: 10.1016/j.trsl.2020.03.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
23 Naidu SK, Nabi R, Cheemarla NR, Stanfield BA, Rider PJ, Jambunathan N, Chouljenko VN, Carter R, Del Piero F, Langohr I, Kousoulas KG. Intramuscular vaccination of mice with the human herpes simplex virus type-1(HSV-1) VC2 vaccine, but not its parental strain HSV-1(F) confers full protection against lethal ocular HSV-1 (McKrae) pathogenesis. PLoS One 2020;15:e0228252. [PMID: 32027675 DOI: 10.1371/journal.pone.0228252] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
24 Rider PJF, Uche IK, Sweeny L, Kousoulas KG. Anti-viral immunity in the tumor microenvironment: implications for the rational design of herpes simplex virus type 1 oncolytic virotherapy. Curr Clin Microbiol Rep 2019;6:193-9. [PMID: 33344108 DOI: 10.1007/s40588-019-00134-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
25 Bernstein DI, Morello CS, Cardin RD, Bravo FJ, Kraynyak KA, Spector DH. A vaccine containing highly purified virus particles in adjuvant provides high level protection against genital infection and disease in guinea pigs challenged intravaginally with homologous and heterologous strains of herpes simplex virus type 2. Vaccine 2020;38:79-89. [PMID: 31611098 DOI: 10.1016/j.vaccine.2019.09.090] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
26 Bernstein DI, Cardin RD, Bravo FJ, Hamouda T, Pullum DA, Cohen G, Bitko V, Fattom A. Intranasal nanoemulsion-adjuvanted HSV-2 subunit vaccine is effective as a prophylactic and therapeutic vaccine using the guinea pig model of genital herpes. Vaccine 2019;37:6470-7. [PMID: 31515143 DOI: 10.1016/j.vaccine.2019.08.077] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
27 Srivastava R, Roy S, Coulon PG, Vahed H, Prakash S, Dhanushkodi N, Kim GJ, Fouladi MA, Campo J, Teng AA, Liang X, Schaefer H, BenMohamed L. Therapeutic Mucosal Vaccination of Herpes Simplex Virus 2-Infected Guinea Pigs with Ribonucleotide Reductase 2 (RR2) Protein Boosts Antiviral Neutralizing Antibodies and Local Tissue-Resident CD4+ and CD8+ TRM Cells Associated with Protection against Recurrent Genital Herpes. J Virol 2019;93:e02309-18. [PMID: 30787156 DOI: 10.1128/JVI.02309-18] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
28 Bernstein DI, Cardin RD, Pullum DA, Bravo FJ, Kousoulas KG, Dixon DA. Duration of protection from live attenuated vs. sub unit HSV-2 vaccines in the guinea pig model of genital herpes: Reassessing efficacy using endpoints from clinical trials. PLoS One 2019;14:e0213401. [PMID: 30917165 DOI: 10.1371/journal.pone.0213401] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]